CAT

904.45

-1.01%↓

295.22

-0.87%↓

GEV.US

1,065.1

-0.91%↓

RTX

178.83

-0.48%↓

241.07

+1.61%↑

CAT

904.45

-1.01%↓

295.22

-0.87%↓

GEV.US

1,065.1

-0.91%↓

RTX

178.83

-0.48%↓

241.07

+1.61%↑

CAT

904.45

-1.01%↓

295.22

-0.87%↓

GEV.US

1,065.1

-0.91%↓

RTX

178.83

-0.48%↓

241.07

+1.61%↑

CAT

904.45

-1.01%↓

295.22

-0.87%↓

GEV.US

1,065.1

-0.91%↓

RTX

178.83

-0.48%↓

241.07

+1.61%↑

CAT

904.45

-1.01%↓

295.22

-0.87%↓

GEV.US

1,065.1

-0.91%↓

RTX

178.83

-0.48%↓

241.07

+1.61%↑

Начало・Списък с акции・Ocugen Inc

Ocugen Inc

Отворен

1.46

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.45

Максимум

1.48

Ключови измерители
By Trading Economics
Приходи	-1.5M -19M
Продажби	1.7M 1.5M
EPS	-0.06
Марж на печалбата	-1,250.946
Служители	116
EBITDA	-987K -17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+687.07% upside

Дивиденти
By Dow Jones
Следващи печалби	31.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-125M 501M
Предишно отваряне	1.46
Предишно затваряне	1.46

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

0.6818 / 0.74 Подкрепа & съпротива

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.05.2026 г., 22:50 ч. UTC

Печалби

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12.05.2026 г., 22:49 ч. UTC

Печалби

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12.05.2026 г., 22:32 ч. UTC

Печалби

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12.05.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Печалби

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12.05.2026 г., 22:26 ч. UTC

Печалби

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12.05.2026 г., 22:25 ч. UTC

Печалби

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12.05.2026 г., 22:25 ч. UTC

Печалби

Aristocrat Leisure Interim Dividend A$0.50/Security

12.05.2026 г., 22:24 ч. UTC

Печалби

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12.05.2026 г., 22:23 ч. UTC

Печалби

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12.05.2026 г., 22:23 ч. UTC

Печалби

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12.05.2026 г., 22:19 ч. UTC

Печалби

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12.05.2026 г., 22:14 ч. UTC

Печалби

CBA: Business Lending Continued to Grow Above System>CBA.AU

12.05.2026 г., 22:14 ч. UTC

Печалби

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12.05.2026 г., 22:13 ч. UTC

Печалби

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12.05.2026 г., 22:12 ч. UTC

Печалби

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12.05.2026 г., 22:12 ч. UTC

Печалби

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12.05.2026 г., 22:11 ч. UTC

Печалби

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12.05.2026 г., 22:11 ч. UTC

Печалби

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12.05.2026 г., 22:10 ч. UTC

Печалби

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12.05.2026 г., 22:09 ч. UTC

Печалби

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12.05.2026 г., 22:09 ч. UTC

Печалби

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12.05.2026 г., 22:08 ч. UTC

Печалби

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12.05.2026 г., 22:07 ч. UTC

Печалби

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12.05.2026 г., 22:06 ч. UTC

Печалби

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12.05.2026 г., 22:06 ч. UTC

Печалби

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12.05.2026 г., 22:05 ч. UTC

Печалби

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

687.07% нагоре

12-месечна прогноза

Среден 11.57 USD 687.07%

Висок 22 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.6818 / 0.74Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.